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Activation of zygotic gene expression in the two-cell mouse embryo is associated with destruction of maternally inherited
transcripts, an important process for embryogenesis about which little is understood. We asked whether the Argonaute
(Ago)/RNA-induced silencing complex, providing the mRNA “slicer” activity in gene silencing, might contribute to this
process. Here we show that Ago2, 3, and 4 transcripts are contributed to the embryo maternally. By systematic knockdown
of maternal Ago2, 3, and 4, individually and in combination, we find that only Ago2 is required for development beyond
the two-cell stage. Knockdown of Ago2 stabilizes one set of maternal mRNAs and reduces zygotic transcripts of another
set of genes. Ago2 is localized in mRNA-degradation P-bodies analogous to those that function in RNAi-like mechanisms
in other systems. Profiling the expression of microRNAs throughout preimplantation development identified several
candidates that could potentially work with Ago2 to mediate degradation of specific mRNAs. However, their low
abundance raises the possibility that other endogenous siRNAs may also participate. Together, our results demonstrate
that maternal expression of Ago2 is essential for the earliest stages of mouse embryogenesis and are compatible with the
notion that degradation of a proportion of maternal messages involves the RNAi-machinery.
INTRODUCTION
The transition from maternal to zygotic regulation is the first
major transition that occurs after fertilization and comprises
a dramatic reprogramming of gene expression that is essen-
tial for the development of most organisms. The timing of
embryonic gene activation is species-specific (Manes, 1973;
Camous et al., 1986; Braude et al., 1988; Crosby et al., 1988;
Zernicka-Goetz, 1994; Hoffert et al., 1997). In mouse a major
burst of zygotic gene expression occurs at the two-cell stage
corresponding to the time at which mRNAs for the majority
of maternal transcripts are degraded (Schultz, 1993). Global
expression profiles have identified distinctive patterns of
maternal mRNA degradation and zygotic genome activation
in the mouse (Hamatani et al., 2004; Wang et al., 2004).
However, little is known about the regulation of maternal
mRNA stability and factors involved in mRNA degradation
pathways at these early stages of mouse development. Be-
cause gene-silencing events mediated through the RNA-
induced silencing complex (RISC) are proving to play key
developmental roles and work in part through regulating
mRNA destruction, we considered whether this complex
might contribute to the mechanism for degradation of ma-
ternal transcripts in the mouse embryo.
In most eukaryotes, repression by RISC can be mediated
through several mechanisms in response to double-stranded
RNA (dsRNA; for review see Denli and Hannon, 2003; Meis-
ter and Tuschl, 2004; Filipowicz, 2005; Sen and Blau, 2006;
Valencia-Sanchez et al., 2006; Rana, 2007): by regulation of
heterochromatic silencing and histone H3 K9 methylation
(Volpe et al., 2002), inhibition of translation (Liu et al., 2004;
Meister et al., 2004, Pillai et al., 2004), or sequence-specific
cleavage of mRNA (Tuschl et al., 1999; Zamore et al., 2000;
Hannon, 2002). On the other hand, activation by RISC has
also been observed at both transcriptional (Li et al., 2006) and
translational (Vasudevan and Steitz, 2007) levels. The trigger
of these processes can be provided exogenously, for exam-
ple, by interfering dsRNA, or endogenously by, for example,
microRNAs (miRNAs) or other endogenous small RNAs.
Within cells, either 21–24–nucleotide short interfering RNA
(siRNA) fragments derived from longer dsRNA or miRNAs
(Hammond et al., 2001; Hutvagner and Zamore, 2002;
Mourelatos et al., 2002; Doi et al., 2003) can be incorporated
into the RISC together with an Argonaute protein whose
PAZ domain facilitates RNA recognition. Mammalian cells
have several Argonaute-like genes, but only Ago2 has been
shown to be required for RNA cleavage (Liu et al., 2004).
MiRNAs are short noncoding RNAs that inhibit transla-
tion and lead to mRNA instability (Roush and Slack, 2006).
Although still little is known about their in vivo function, it
has been demonstrated that miR-430 promotes deadenyla-
tion and clearance of maternal mRNAs in zebrafish embryos
(Giraldez et al., 2006). Inhibited mRNAs as well as miRNAs
may accumulate in cytoplasmic processing bodies (P-bodies)
together with the enzymes required for mRNA degradation
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(Liu et al., 2005a; Pillai et al., 2005; Sen and Blau, 2005). There
are 500–1000 miRNA genes in vertebrates and plants, and
each miRNA is predicted to target hundreds of mRNAs
(Bushati and Cohen, 2007).
RNA interference (RNAi) was first demonstrated to be
effective in mammalian cells through experiments in which
long dsRNAs were successfully used to silence gene activity
in mouse oocytes and early preimplantation embryos (Svo-
boda et al., 2000; Wianny and Zernicka-Goetz, 2000). This
indicated that these cells ought to contain components of the
enzymatic machinery required for the silencing process in-
volving Argonaute proteins. It also raised the question of
what the natural function of silencing might be at these early
embryonic stages. Yet, eliminating zygotic expression of
Ago2, the catalytic component of the RISC, indicated that
there was no requirement for Ago2 until only after implan-
tation (Liu et al., 2004; Morita et al., 2007) when it is involved
in gastrulation and mesoderm formation (Alisch et al., 2007).
However, it remained possible that Ago2 is supplied mater-
nally for functions in the early embryo (from Ago2/
mothers). Alternatively, its function could be substituted by
one of the other members of the Argonaute family. We
addressed these questions by first examining which of the
Argonaute family members are present in oocytes and pre-
implantation embryos and then by systematically depleting
them in combination or individually. We found that both
Ago2 and 3 are expressed throughout early mouse develop-
ment. However, only specific elimination of Ago2 tran-
scripts leads to developmental arrest at the two-cell stage.
This is reflected in the stabilization of one set of maternal
mRNAs. This also leads to the reduction in the appearance
of zygotic transcripts of another set of genes. To explore a
possible link between the observed mRNA stabilization of
maternal transcripts by Ago2 and the endogenous miRNAs,
we carried out miRNA screen and a bioinformatics search.
This pointed to multiple miRNAs as potential candidates for
the degradation of specific maternal messages in the two-cell
embryo. However, this does not exclude the possible in-
volvement of other natural endoegous siRNAs present in
mouse oocytes and early embryos. Taken together, our re-
sults demonstrate an essential role for Ago2, a maternally
expressed gene, at the earliest stages of mouse embryogen-
esis and indicate that Ago2, directly or indirectly, is required
for degradation of a set of maternal transcripts to support
development beyond two-cell-stage.
MATERIALS AND METHODS
Embryo Collection and Culture
F1 (C57BL/6xCBA) females were injected with 5 IU pregnant mare’s serum
gonadotrophin (PMSG; Folligon, Intervet, Cambridge, United Kingdom) and
with 5 IU human chorionic gonadotrophin (hCG; Chorulon, Intervet) 48 h
later to induce ovulation as described (Hogan et al., 1994). Embryos were
collected in M2 medium and cultured in drops of KSOM supplemented with
amino acids and 4 mg/ml BSA, under paraffin oil in an atmosphere of 5% CO2
in air at 37.5°C. Zygotes for RNA injections were collected from female mice
25 h after hCG. Two-, four-, and eight-cell embryos for in situ hybridization
were collected 46 or 56 or 64 h after hCG, respectively. Morula and blastocysts
were collected after 2.5 or 3 d, respectively. All animals were handled in
accordance with Home Office legislation.
RNA In Situ Hybridization
Freshly collected embryos at various stages were fixed in 4% paraformalde-
hyde in PBS. In situ hybridizations were performed as described (Wilkinson
and Nieto, 1993; Hogan et al., 1994), except that the embryos were not
dehydrated and the proteinase K treatment was omitted. Color visualization
of the alkaline phosphatase was done using precipitating BM purple substrate
according to manufacturer’s instructions (Roche, Indianapolis, IN).
GFP and DsRed Constructs
GFP-Ago2 was constructed by amplifying full-length Ago2 from a two-cell
embryo using the Superscript One-Step RT-PCR for long templates (Invitro-
gen, Carlsbad, CA). Gene specific primers (Supplementary Table S1) were
tagged with BamHI to amplify the full-length open reading frame (ORF) of
Ago2 to allow cloning in frame with the GFP gene. Reporter plasmid for
DsRed protein expression (pDsREd2-N1, BD Bioscience Clontech, San Jose,
CA) was constructed by amplifying the full-length ORF for Dcp1a with
gene-specific primers (Supplementary Table S1) using EcoRI and KpnI sites
and the subsequence subcloned the DsREd-Dcp1a into the pRN3 vector using
EcoRI and NotI to replace the GFP gene in order to allow for T3 mMessage
transcription (Ambion, Austin, TX).
RNA Synthesis and Microinjections
The templates used for dsRNA synthesis were PCR product. Oligonucleotides
were linked with T7 promoter sites, and a 500–600–base pair PCR fragment
was amplified. The primers used for generating dsRNA for Ago2, 3, and 4 are
listed in Supplementary Table S1. Full-length MmGFP cDNA was done as
previously described (Wianny and Zernicka-Goetz, 2000).
RNAs were synthesized using the T3 or T7 polymerase, using the Megas-
cripts Kit (Ambion) for dsRNA and the mMessage for capped mRNA (Am-
bion). DNA templates were removed with DNase treatment. The RNA prod-
ucts were extracted with phenol/chloroform and ethanol-precipitated. To
anneal sense and antisense RNAs, equimolar quantities of sense and antisense
RNAs were mixed in the annealing buffer (10 mM Tris, pH 7.4, 0.1 mM EDTA)
to a final concentration of 2 M each, heated for 10 min at 68°C, and incubated
at 37°C for 3–4 h. To avoid the presence of contaminating single-stranded
RNA in the dsRNA samples, the preparations were treated with 2 g ml–1
RNase T1 (Calbiochem, Nottingham, United Kingdom) and 1 g ml1 RNase
A (Sigma, Poole, Dorset, United Kingdom) for 30 min at 37°C. The dsRNAs
were then treated with 140 g ml1 proteinase K (Sigma), phenol/chloro-
form-extracted, and ethanol-precipitated. Formation of dsRNA was con-
firmed by migration on an agarose gel. RNAs were diluted in water, to a final
concentration of 1 mg/ml. siRNA SMART pool was obtained from Dhar-
macon; for Ago3 (siGenome SMARTpool M-054947-00-0005) and a nontarget-
ing negative control pool (D-001206-13-05). The siRNA SMART pool was
resuspended in 250 l 1 siRNA buffer (20 mM KCl, 6 mM HEPES buffer (pH
7.5) and 200 M MgCl2) to give a final concentration of 20 M according to
the manufacturer’s instructions.
The dsRNA or siRNA were microinjected, as described before, and each
embryo was injected with10 pl dsRNA (Wianny and Zernicka-Goetz, 2000).
Rhodamine-conjugated dextran (D-3308, Molecular Probes, Eugene, OR) was
added to all RNA injections to identify embryos injected successfully. Em-
bryos were observed by either transmitted light or fluorescent light micros-
copy using IP Lab software (Scanalytics, Billerica, MA).
RT-PCR Analysis
RT-PCR of RNA-injected embryos was performed using the Superscript
One-Step RT-PCR with Platinum Tag (Invitrogen). The RT-PCR was done
according to the manufacturer’s instructions with some modifications:
Pools of four embryos were lysed in the RT buffer (1 reaction mix, 0.2 M
each of sequence specific primers) by heating to 65°C for 2 min and were
left at room temperature for 2 min to allow annealing to the primers before
left on ice before adding the Superscript/platinum tag. Oligo d(T) primed
first-strand cDNA was synthesized as follows: 50°C for 30 min, 94°C for 2
min, and then 40 cycles of 94°C for 15 s, 55°C for 30 s, and 68°C for 30 s.
with extension for 10 min at 72°C. PCR products were visualized on a 1.5%
agarose gel containing ethidium bromide for UV visualization. All DNA
oligonucleotides used for RT-PCR analysis are listed in Supplementary
Table S1. All accession numbers for genes tested are listed in Supplemen-
tary Table S1.
cDNA Synthesis and Subtractive Hybridization
(Representational Difference Analysis)
Construction of cDNA libraries from single cells and the representational
difference analysis (RDA) were done as previously described (Hubank and
Schatz, 1994; Dulac and Axel, 1995; Saitou et al., 2002) with a few modifica-
tions. Briefly, the embryo was lysed at 65°C for 1 min in lysis buffer (0.5%
NP40, 1.25 mM each of dATP, dCTP, dGTP, and dTTP, 1 l of 50 OD/ml oligo
d(T)24, 0.4 U primeRNase inhibitor [Roche] and 0.38 U RNAguard [Amer-
sham Biotechnology, Piscataway, NJ [ in 1 MMLV (Moloney murine leuke-
mia virus) buffer (Roche). The reaction was allowed to cool down at RT for 1
min and kept on ice before adding AMV-and MMLV-reverse transcriptases
according to the manufacturer’s instructions (Roche). cDNA libraries for
subtractive hybridization were further treated with the tailing reaction using
terminal deoxynucleotidyltransferase according the manufacturer’s instruc-
tions (10533-065, Invitrogen) and subsequently amplified using the OL-1
primer to allow the insertion of restriction enzyme site. All oligonucleotides
used in RT-PCR analysis for Argonaute 1-4 and control primers used in the
subtractive hybridization are listed in Supplementary Table S1. Double-
stranded cDNA from Ago2/3-depleted two-cell embryos were used as the
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tester, and cDNA from untreated two-cell embryos was used as the driver
using a ratio of 1:100 for the first round for selection and 1:800 for the two after
rounds of selections. The cDNAs were used as tester and driver, respectively,
for the forward subtraction and vice versa for reverse subtraction. Tester and
driver cDNAs were hybridized, and the hybrid sequences were removed.
Consequently, the nonhybridized cDNAs represent fragments corresponding
to modulated or on/off-switched sequences. Differentially expressed genes
were amplified from the subtracted cDNA using suppression PCR. A Gene-
Amp 2700 (PE Biosystems, Warrington, United Kingdom) was used for ther-
mal cycling. The conditions used were 94°C for 10 s, 68°C for 30 s, and 72°C
for 90 s, for 20 cycles (the initial PCR), and 20 cycles (for the nested PCR). PCR
amplicons from the tester, driver, and subtracted cDNA were electrophoresed
on a 2% agarose gel, and prominent amplicons specific to the subtracted
cDNA were excised from the gel. PCR analysis consists in the amplification of
the housekeeping gene for -actin, -tubulin, and Oct4 cDNA in order to
evaluate its expression in subtracted and unsubtracted cDNAs. All DNA
oligonucleotides used for RT-PCR analysis are listed in Table S1 in Supple-
mentary Material.
Micro-RNA Microarrays and Their Target Prediction
For miRNA microarray expression analysis total RNA was extracted from
pools of 20 MII oocytes, 20 zygotes (25–26 h after hCG), 20 two-cell embryos
(32–33 h after hCG), 20 two-cell embryos (47 h after hCG), 20 four-cell
embryos (56–57 h after hCG), 20 eight-cell embryos (67–68 h after hCG), and
20 blastocysts (87–90 h after hCG) by adding 100 l Trizol (Invitrogen). RNA
labeling and hybridizations were carried out as described previously (Miska
et al., 2004).
Microarrays used were custom-made and represented all human miRNAs
according to miRBase release 8.0 (Griffiths-Jones, 2004; Griffiths-Jones et al.,
2006). Probe design was carried out as described previously (Miska et al.,
2004). For probe set and microarray data, see Supplementary Tables S2 and
S3, respectively. Microarray slides were scanned using an Axon 4000B scan-
ner (Molecular Devices, Sunnyvale, CA), and primary data were analyzed
using the GenePix 6.0 (Molecular Devices) software. Each probe was repre-
sented by four spots on the microarray. Median signal intensities with local
background subtraction for each spot were used for subsequent analyses. The
median of the four spots for each probe was used to represent the signal for
each probe. Interarray comparison was performed through array normaliza-
tion through RNA spikes added before RNA labeling (Wienholds et al., 2005).
MiRNA target prediction was performed using the RNAfold program,
which is part of the Vienna RNA Package (Mathews et al., 1999). The program
was used to find the predicted binding between the miRNA and successive
short sections of the mRNA sequence; thus scanning the mRNA for candidate
binding sites. RNAfold yields a predicted fold structure and associated bind-
ing energy, in computer readable format, as output. RNAfold finds a mini-
mum energy fold for a continuous RNA sequence, and this is exploited in this
application to predict the binding of one sequence to another by computa-
tionally attaching the miRNA to each successive section of the mRNA in the
correct orientation to with a flexible linker of Ns. We used mRNA sections 12
nucleotides longer than the miRNA, with a 12-mer N-linker and jumped three
nucleotides between successive positions. We discarded all binding patterns
that showed any loops in addition to a single “hairpin” between the mRNA
section and the miRNA and tabulated the remaining binding sites for com-
parison between the miRNAs.
RESULTS
Ago2 Is Expressed in Preimplantation Embryos and
Localizes to Cytoplasmic mRNA Decay P-Bodies
To examine a possible role of Argonaute proteins in the early
mouse embryo, we first analyzed the expression of four
Argonaute family members during preimplantation devel-
opment, by performing gene-specific PCR on oligo d(T)
first-strand cDNA (Figure 1A). We found that Ago2 and 3
mRNAs are expressed in oocytes and throughout all preim-
plantation stages, suggesting their gene products may be
required maternally and zygotically. Ago4 mRNA was also
present in oocytes and zygotes, but was down-regulated by
the four-cell stage, suggesting a function restricted to oogen-
esis and the zygote. We were not able to detect a transcript
for Ago1 throughout preimplantation development. Inter-
estingly, mRNA for all four Argonaute genes was detected
in embryonic stem cells (Figure 1A). Although we detected
only one band of correct size for each PCR reaction, each
PCR product was subjected to DNA sequencing to confirm
its identity (data not shown), because of the high degree of
similarity between the Argonaute members. For each RT-
PCR, control transcripts for -actin and -tubulin were in-
cluded (Figure 1A).
To determine whether the localization of Ago2 or 3 tran-
scripts show any spatial differences in preimplantation em-
bryos, we carried out RNA in situ hybridization (Figure 1 in
Supplementary Material). Detection of both Ago2 and 3 was
weak at the early stages (two- to eight-cell embryos). As the
inner cells form, expression appeared stronger and was
enriched progressively within, but not restricted to, the in-
ner cells and then the inner cell mass (ICM) of the blastocyst.
In situ expression profiles of Ago2 and 3 transcripts were
also shown to be similar at later postimplantation stages (Liu
et al., 2004).
Because Ago2 protein has been shown to localize to P-
bodies (Liu et al., 2005b; Sen and Blau, 2005) that serve as
sites for mRNA destruction and decay (Sheth and Parker,
2003), we also wanted to examine its spatial distribution in
the mouse embryo. To this end, we generated a construct
encoding Ago2-green fluorescent protein (GFP) fusion pro-
tein and microinjected its synthetic message into zygotes
and examined its distribution at the two-cell stage. This
revealed that Ago2-GFP localizes to vesicle-like bodies that
resembled the cytoplasmic P-bodies (Figure 1B). To assess
whether the Ago2-containing bodies could be indeed P-
bodies, we coinjected zygotes with synthetic, tagged mRNA
for both Ago2-GFP and Dcp1a, a decapping protein that
localizes to P-bodies and is required for functional miRNA
RNAi (Behm-Ansmant et al., 2006) fused to DsRed (Dcp1a-
DsRed). This showed that Ago2-GFP distribution was over-
lapping with that of the decapping enzyme Dcp1a-DsRed
(Figure 1B).
Thus, these experiments indicate that there is a maternal
contribution of Argonaute transcripts to early mouse em-
bryos, and specifically Ago2 and 3 mRNAs are present
throughout the preimplantation stages. Moreover, the spa-
tial localization of Ago2 in the mouse embryo is similar to
the localization of Ago2 in other cell types (Liu et al., 2005b;
Sen and Blau, 2005).
Ago2 Knockdown Leads to Early Developmental Arrest
To assess the functional role of Argonaute proteins ex-
pressed in early mouse embryo, we used RNAi. We first
showed that control embryos, both noninjected (Figure 2A)
and injected as late zygotes with GFP dsRNA (Figure 2B),
still expressed Ago2, 3, 4, -actin, or the POU domain, class
5, transcription factor 1 (POU5F1, also known as Oct4)
mRNAs 20–24 h after injection, as indicated for each gel.
These control-injected embryos developed to the blastocyst
stage as efficiently as noninjected embryos (Figure 2, A and
B). We subsequently synthesized a 501-nucleotide dsRNA
complementary to Ago3 transcript sequences. This sequence
also had 74% identity to Ago2 and consistently when in-
jected into mouse zygotes was able to down-regulate both
Ago2 and 3 transcripts (Figure 2C) as revealed by RT-PCR.
We found that the majority (80%: 42/54 embryos, five inde-
pendent experiments) of such embryos arrested develop-
ment at the two-cell stage and none developed to the blas-
tocyst stage (Figure 2C). To determine whether this
embryonic arrest was due to elimination of Ago2, 3, or both,
we injected dsRNA targeted against specific sequences in
the 5 end of the ORF of Ago2 mRNA. This resulted in 90%
knockdown of Ago2 mRNA, but not Ago3 mRNA, and led
to a similar phenotype of developmental arrest (76%:
29/38 embryos, three independent experiments) at the
two-cell stage (Figure 2D).
In an attempt to specifically suppress Ago3 mRNA, we
carried out RNAi using SMARTPool siRNA (Dharmacon),
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as we were unable to design long dsRNA to down-regulate
expression of Ago3 mRNA only. Microinjection of siRNAs
against Ago3 mRNA into zygotes revealed a reduction in
the Ago3 transcript by the two-cell stage (Figure 2E), but the
injected embryos were still capable of developing to the
blastocyst stage. A siRNA control group showed normal
expression of Ago2 and 3 mRNAs and also developed to the
blastocyst stage (Figure 2F).
The expression of Ago4 mRNA declines by the four-cell
stage, where the Ago4 transcript cannot be detected. Con-
sistent with its temporal expression profile (Figure 1A), tran-
scripts of Ago4 were not detectable when expression was
analyzed 20–24 h after injection of dsRNA against GFP,
Ago2 and 3 mRNAs (Figure 2, B and C). Therefore, in order
to assess if Ago4 transcript might be important in two-cell
embryos, we attempted to deplete Ago4 transcript from the
Figure 1. Ago2, 3, and 4 transcripts are expressed in oocytes and at early stages of development, with Ago2 and 3 transcripts in all
preimplantation stages tested. (A) PCR analysis of Ago1-4 gene family on preimplantation mouse first-strand cDNA from different stages. As
a positive control for the PCR amplification, a band was successfully amplified for all Argonautes in ES cells. Actin and tubulin were used
as control genes. (B) Localization of Ago2-GFP fusion protein in mRNA decay centers. Confocal laser microscopy images of two-cell embryos
microinjected at zygote stage with tagged mRNA for Ago2-GFP and Dcp1a-DsRed. Top panel, vesicle-like localization of Ago2-GFP and
Dcp1a-DsRed fusion proteins in a two-cell embryo (96 M 96 M). Bottom panel, a higher magnification of one blastomeres in the two-cell
embryo expressing Ago2-GFP and DsRed-Dcp1a (46 M 46 M). Green, red, and orange arrowheads point to examples of vesicles showing
localization of Ago2-GFP, DsRed-Dcpla, and Ago2-GFPDsRed-Dcpla, respectively.
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early two-cell stage (when the Ago4 transcript is still detect-
able in control embryos). This resulted in a depletion of the
Ago4 transcript and also in an 50% reduction of the Ago3
transcript, but still allowed embryos to develop to the blas-
tocyst stage (80% developed to blastocyst: 48/60, two inde-
pendent experiments; Figure 2G). The control RNAi em-
bryos at 14 h after injection showed expression of Ago2, 3,
and 4 transcripts (Figure 2H) and developed to blastocyst
stage as expected (85% developed to blastocyst; 41/48, two
independent experiments). For RNAi experiments directed
specifically against Ago2, 3, and 4, we have also assessed the
endogenous Oct4 mRNA. The expression of Oct4 mRNA
remained unchanged, indicating the specificity of the effect.
A summary of all RNAi experiments is schematically pre-
sented in Figure 2 in Supplementary Material.
Thus together these experiments suggest that maternally
provided Ago2 mRNA is required to permit development of
the mouse embryo beyond the two-cell stage.
Ago2 Depletion Results in Stabilization of Some Maternal
mRNAs in the Two-Cell Embryo
Maternal factors are known to control development before
the activation of the embryonic genome at the two-cell stage
(Paynton and Bachvarova, 1988; Bashirullah et al., 2001; Oh
et al., 2000). We considered that one possible explanation for
the developmental arrest of Ago2-depleted embryos was
that RISC-mediated silencing might be required to destroy a
subset of maternal RNAs to facilitate further development. If
this were the case, it would suggest that after knockdown of
Figure 2. Ago2 is required for development
beyond the two-cell stage. Early zygotes were
injected with dsRNA for GFP or dsRNA or
siRNA for combinations or individual Argo-
naute genes (as indicated) or were not injected.
The embryos were cultured in vitro until the
blastocyst stage. Images were taken using flu-
orescence light to identify embryos injected
with both RNA and rhodamine-conjugated
dextran (except the noninjected control group,
shown as bright-field microscopy images). Em-
bryos are shown at the two-cell stage (20–24 h
after injection) and 3 d after injection when con-
trol embryos developed to blastocyst stage. Em-
bryos of each experimental group were scored
according to their developmental progress. The
number of embryos in each experiment is indi-
cated as follows: injected embryos (two-cell stage;
IE2), arrested embryos (A), embryos developed
to blastocyst stage (EB) and embryos fragmented
or lysed (D). (A) noninjected control group (IE2
26, EB  23, D  3; (B) RNAi GFP: dsRNA for
GFP control (IE2 39, EB 30, D 9); (C) RNAi
Ago2Ago3 (IE2 54, A 42, EB 0, D 12);
(D) RNAi Ago2 (IE2  38, A  29, EB  0, D 
9); (E) siRNAi Ago3 (IE2  29, EB  21, D  8);
and (F) siRNAi control (IE2  77, EB  63, D 
14). The right side of each injection experiment
shows RT-PCR analysis performed on two-cell
embryos for Ago2, 3, 4, actin, or Oct4, as indi-
cated. RT-PCR was done 20–24 h after injection,
corresponding to 46–50 h after hCG, as indicated.
(G) RNAi Ago4 (IE2  60, EB  48, D  12). (H)
RNAi control (IE2 48, EB 41, D 7). RT-PCR
analysis performed on Ago2, 3, 4, and Oct4, as
indicated. RT-PCR was done 14 h after injection,
corresponding to 40 h after hCG, as indicated.
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Ago2 mRNA we might see the stabilization of some mater-
nal transcripts and a failure of other transcripts to appear. To
address this we performed a subtractive hybridization be-
tween wild-type control and Ago2-depleted two-cell stage
embryos and also examined the expression of other genes
previously shown by microarray analysis to be expressed
around the time of this developmental transition (Wang et
al., 2004).
Our subtractive screen revealed genes that showed strong
changes in expression pattern after Ago2 RNAi as shown by
nested PCR on oligo d(T) first-strand cDNA on two-cell
control and Ago2-depleted embryos. This showed that both
the mouse oocyte-specific gene (Mosg) and the gastrulation
brain homeobox gene 2 (Gbx2) transcripts appeared to be
stabilized in the Ago2 RNAi two-cell embryos, whereas in
control embryos they undergo substantial degradation dur-
ing the two-cell stage (Figure 3A). This suggests that Ago2
function might be required to degrade these maternal
mRNAs. We have also seen the decreased expression of
Cyclin E2 (Ccne2) mRNA upon Ago2 RNAi (Figure 3A).
Levels of expression of control genes such as -actin, -
tubulin, and Oct4 were consistent (Figure 3A). These exper-
iments were also carried out in parallel using a gene-specific
RT-PCR approach on two-cell control and Ago2-depleted
embryos, which showed consistent results ensuring that no
artifacts were introduced during generation of oligo d(T)
cDNA libraries of two-cell stage embryos (see Supplemen-
tary Material, Figure S3).
As a complementary approach we also interrogated our
previous microarray gene profiling data (Wang et al., 2004)
to identify maternal mRNAs known to be down-regulated at
the maternal to zygotic transition and selected 16 of these for
detailed analysis as a possible candidates for regulation by
the RISC/Ago2 machinery. The genes selected in this way
were chosen at random to avoid bias toward any particular
biological pathway or specific functions in the maternal to
zygotic transition. Seven of the 16 genes analyzed displayed
altered transcript level after Ago2 RNAi (Figure 3, B and C).
We found stabilization of fibroblast growth factor receptor 2
(Fgfr2) and leptin receptor 2 (Lepr2) transcripts (Figure 3B),
suggesting that Ago2 might normally be required to de-
grade these maternal mRNAs. In contrast we found that
transcripts for proteasome subunit 3 (Psme3), hematopoiet-
ically expressed homeobox (Hhex), p27/ARID1A (sub-
unit of the SWI/SNF complex), dynein, cytoplasmic, IC 2
(Dncic2), and fibroblast growth factor 9 (Fgf9) were down-
regulated upon Ago2 depletion, in contrast to the control
group, where all transcripts were detected (Figure 3C). On
the other hand, a number of other gene transcripts (bone
morphogenetic protein 15 (Bmp15), Oct4, -actin, -tubulin,
and a mitogen-activated protein binding protein interacting
protein (MAPBPIP) showed no significant difference be-
tween the control and Ago2 dsRNA treated embryos (data
not shown).
To test whether the two-cell arrest phenotype caused by
Ago2 depletion could indeed be linked to the specific regu-
lation of the switch from maternal to zygotic expression, we
chose to compare the effects of knocking down aurora kinase
C, a maternally contributed protein that is required for cell
cycle progression (Petersen et al., 2001). When dsRNA
against aurora kinase C was microinjected into zygotes, it
resulted in 90% of reduction of aurora kinase C and also
led to a two-cell arrest as a result of failure of cell division
(Figure 4A). RNAi control embryos showed no developmen-
tal arrest and developed to blastocyst stages (Figure 4A). We
then examined whether genes showing altered expression in
the RNAi Ago2 two-cell embryos were similarly affected
after aurora kinase C RNAi. As before, we assessed the
expression of these genes by nested PCR on first-strand
cDNA generated from control and aurora kinase C RNAi
two-cell embryos (Figure 4B, three independent experi-
ments). This showed that mRNA levels of the maternally
expressed genes Mosg, Gbx2, Fgfr2, and Lepr2 were neither
stabilized nor up-regulated after aurora kinase C depletion
as they were after Ago2 RNAi (compare Figure 3, A–C, with
4B). Moreover, transcripts which were strongly down-regu-
lated in the Ago2-depleted embryos (psme3, Hhex, p27/
ARID1A, Dncic2, Fgf9; Figure 3C), showed no reduction in
expression in either control or aurora kinase C RNAi em-
bryos (Figure 4B). This indicates that these changes in gene
expression specifically require functional Ago2 in two-cell
embryos.
Possible Involvement of Small Endogenous RNAs in
Destruction of Specific Maternal Messages in the
Two-Cell Embryo
Degradation of mRNAs by Ago2 with the RISC complex
generally requires that these mRNAs must contain target
sites for one or more miRNAs or other endogenous siRNAs.
We therefore performed a miRNA-microarray screen, ask-
ing which mouse counterparts of an array of human miRNA
sequences could be detected at developmental stages from
MII oocytes to blastocysts (Supplementary Tables S2 and
S3). From the resultant data we identified 24 miRNAs that
were present in either the early or late two-cell embryos that
could therefore be candidates to mediate degradation of
maternal transcripts. We then used the sequence of the
Figure 3. Transcripts identified with significant different
expression in Ago2-depleted two-cell embryos. RNAi GFP
and RNAi Ago2 embryos were tested for differential gene
expression using gene-specific primers on first-strand cDNA.
(A) Nested PCR for Mosg, Gbx2, and Ccne2 on oligo d(T)
first-strand cDNA. mRNAs for Mosg and Gbx2 maintained
their expression in RNAi Ago2 embryos, in contrast to RNAi
GFP embryos Ccne2 mRNA was not detected in RNAi Ago2
embryos, in contrast to RNAi GFP embryos (B) Nested PCR
on oligo d(T) first-strand cDNA for Fgfr2 and Lepr2 mRNA
shows expression in RNAi Ago2 in contrast to RNAi GFP
embryos, where no expression could be detected. (C) Nested
PCR on oligo d(T) first-strand cDNA for Psme3, Hhex, p27/
ARID1A, Dncic2, Fgf9, and Ago2 mRNAs showed a down-
regulation in Ago2-depleted embryos. All transcripts could
be detected in RNAi GFP embryos.
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corresponding mouse miRNAs to predict computationally
whether any of these miRNAs were likely to target the
mRNAs for Mosg, Gbx2, Fgfr2, and Lepr-2 (Supplementary
Table S4).
Although the precise mechanism of miRNA-mediated
degradation of mRNAs is not clear, some features are widely
accepted and form the basis for most computational meth-
ods for miRNA target prediction. MiRNA target prediction
relies largely on determining the strength and pattern of
binding of the miRNA to the target mRNA in its 3 UTR
region (Rajewsky, 2006). Therefore, we scanned all currently
known mouse miRNAs, extracted from miRBase (http://
microrna.sanger.ac.uk/sequences/index.shtml; Griffiths-Jones,
2004; Griffiths-Jones et al., 2006), looking for the best binding
positions in the 3 UTR, using the RNAfold program
from the Vienna RNA package (http://www.tbi.univie.ac.at/
RNA). We used two indicators for strength of miRNA/
mRNA target prediction: 1) the predicted binding energy of
the miRNA-mRNA duplex, and 2) the presence of “seed
binding” over most of the first eight bases of the miRNA
(Rajewsky, 2006; Sethupathy et al., 2006). We considered an
mRNA a likely miRNA target if the predicted binding en-
ergy was better than 16 kCal/mol or had at least seven
Watson/Crick bonds in the miRNA seed region and a pre-
dicted binding energy better than 8 kCal/mol.
Supplementary Table S4 lists the miRNAs that were
present at either the early or late two-cell embryos and that
are predicted by these criteria to have the potential to target
the mRNAs of Mosg, Gbx2, Fgfr2, and Lepr-2. All four of
these mRNAs gave reasonable target predictions with two
or more miRNAs, making it impossible to tell which of these
specific miRNA would target which mRNA, and indeed it
could be that degradation is achieved by the cumulative
effect of more than one miRNA (Krek et al., 2005b; Saetrom
et al., 2007). In addition, some uncertainty remains, as choice
of the length of the mRNA section to test can influence the
binding patterns and energies. Finally, we would like to note
that it is also possible that other natural siRNAs, for exam-
ple, those derived from pseudogenes (Kawamura et al., 2008;
Tam et al., 2008; Watanabe et al., 2008), might participate in
the RISC complex as partners of Ago2 in the early mouse
embryo.
DISCUSSION
We have found that maternally provided Ago2, best known
as the active endonuclease component of the RISC, is re-
quired for successful development of the early mouse em-
bryos and appears to be involved in the maternal to zygotic
transition. Of the four Argonaute family members, we show
that both Ago2 and 3 transcripts are expressed in oocytes
and throughout the preimplantation development. But only
depletion of Ago2 mRNA leads to the developmental arrest
at the two-cell stage, at the time of the maternal-to-zygotic
transition. GFP-tagged Ago2 colocalizes with the decapping
enzyme, Dcp1a, to cytoplasmic P-bodies, supporting the
hypothesis that Ago2/RISC could be involved in maternal
mRNA degradation. Indeed we have found a subset of
specific individual maternally degraded mRNAs that could
be under the control of this mRNA degradation system as
well as zygotic transcripts which expression fails upon de-
pletion of Ago2 mRNA.
Figure 4. Down-regulation of aurora kinase C
leads to the two-cell arrest, but does not affect
the degradation of maternal mRNAs or zygotic
activation of selected genes. Early zygotes were
injected with dsRNA for GFP or aurora kinase
C. Embryos were cultured in vitro until the
blastocyst stage. Images were taken using flu-
orescence light to identify embryos injected
with both dsRNA and rhodamine-conjugated
dextran. Embryos of each experimental group
were scored according to their developmental
progress. The number of embryos in each ex-
periment is indicated as injected embryos (two-
cell stage; IE2), arrested embryos (A), embryos
that developed to blastocyst (EB), and the num-
ber of embryos fragmented or dead (D). (A)
RNAi GFP-injected control group (IE2  18,
EB  15, D  3) and RNAi aurora kinase C
(Aurkc; IE2  20, A  16, D  4). RT-PCR
analysis was performed 24 h after injection, as
shown on the right panel. Aurkc, aurora kinase
C. This shows that aurora kinase C mRNA is
greatly down-regulated, whereas Ccne2 and
Oct4 mRNA remains constant in both experi-
ments. Nested PCR on first-strand cDNA gen-
erated from either control or RNAi aurora ki-
nase C two-cell embryos. (B) Mosg, Gbx2, Ccne2,
Fgfr2, Lepr2, Psme3, Hhex, p270/ARID1A,
Dncic2, Fgf9, and control genes Ago2, Aurkc,
actin, tubulin, and Oct4. All genes tested showed
similar expression levels of the transcripts as the
control, except aurora kinase C, which was
greatly reduced in the aurora kinase C-depleted
embryos.
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The arrest of Ago2-RNAi embryos, depleted of maternal
Ago2 transcripts from the zygote stage, at the two-cell stage
contrasts to the postimplantation lethality of the Ago2/
embryos, in which zygotic expression of Ago2 is eliminated.
This implies either that Ago2 function is first critical for
progression through these very early developmental stages
but subsequently not until much later or alternatively that a
significant maternal contribution of Ago2 permits develop-
ment through a large part of embryogenesis. The timing of
the observed phenotype after Ago2 knockdown correlates
with the timing of degradation of many maternal mRNAs
and activation of embryonic transcription. It is thus a pivotal
point for changes in patterns in gene expression. Depletion
of Ago2 or aurora kinase C, an Ago2/RISC-unrelated gene,
causes mouse embryos to arrest development at the two-cell
stage. However, the consequences on gene expression are
quite different in these two cases. Down-regulation of Ago2,
but not aurora kinase C, causes the stabilization of some
maternal transcripts that would normally be degraded by
the late two-cell stage. Conversely, whereas Ago2 down-
regulation prevents the onset of expression of a number of
zygotic transcripts, mRNAs for these genes accumulate in
the two-cell stage arrest after aurora kinase C depletion.
Thus, changes in gene expression we describe here appear
specifically to reflect involvement of Ago2 in a gene silenc-
ing process. Intriguingly, not all transcripts tested displayed
altered gene expression upon Ago2 RNAi; for example,
levels of bone morphogenetic protein 15 (Bmp15), Oct4,
-actin, -tubulin, and a MAPBPIP remained unchanged,
indicating that the Ago2 would not be involved in regulat-
ing all transcripts. Ago2 has been shown to be biochemically
distinct from other Argonaute proteins as it is the only one
that is able to catalyze the siRNA-directed mRNA cleavage
(Liu et al., 2004; Okamura et al., 2004). The requirement for
Ago2 during the maternal-zygotic transition and its pres-
ence in cytoplasmic P-bodies therefore provides a hypothe-
sis for a link between Ago2 and siRNA-induced mRNA
instability in the mouse maternal-to-zygotic transition.
Our results point to a possible involvement of Ago2, a
factor best known as a key component of RISC, in degrada-
tion of a set of maternal transcripts in the mouse embryo.
This could be a prerequisite for the onset of a major wave of
zygotic gene transcription at the two-cell stage. The efficient
way in which RNAi can achieve knockdown of Ago2 mRNA
levels and a developmental phenotype within 24 h suggests
the Ago2 maternal contribution is in the form of both protein
and mRNA. Thus, one can hypothesized that a pool of
maternal Ago2 protein would be able to form a RISC com-
plex with the exogenous interfering RNA, whereas the
mRNA pool would be destroyed by this complex and so
would be unable later to supply functional Ago2 protein to
mediate destruction of other maternal mRNAs. This implies
that in normal development there must be a mechanism for
temporal regulation of the translation of maternal Ago2
mRNA at this specific stage. Once translated Ago2 would
then mediate destruction of some other maternal transcripts,
and this would appear necessary to allow zygotic develop-
ment to continue. There is some evidence from a study in
Drosophila (Edgar and Datar, 1996) and in porcine embryos
(Anderson et al., 2001) that degradation of many maternal
mRNAs is indeed necessary to permit zygotically synthe-
sized transcripts and proteins to take control of develop-
ment at the maternal-zygotic transition (Bashirullah et al.,
2001).
During the course of our study examining possible roles
of Argonaute proteins in the early mouse embryos, it was
demonstrated that the RNAi machinery is also used in the
zebrafish embryo to degrade stores of maternal mRNAs
(Giraldez et al., 2006). Analogous to these author’s findings
of the involvement of miR-430 in the degradation of mater-
nal transcripts we have found that the depletion of Ago2
protein does not arrest the embryos in a “maternal state,”
but it appears to be a combination of a maternal and zygotic
state arrest. This might suggest a more universal mechanism
for the Ago2 protein at this specific stage in development in
which Ago2 might not only function to permit degradation
of maternal mRNAs, but also to promote activation of tran-
scription. Indeed such a role for Ago2 has been postulated in
human cell lines (Li et al., 2006). Finally, we would like to
note that Ago2 might also have a slicer-independent role in
the early mouse embryos. Such a role for Ago2 has been
recently demonstrated in hematopoiesis in the regulation of
miRNA homeostasis (O’Carroll et al., 2007; Martinez and
Busslinger, 2007).
The Ago2/RISC factors are essential components of RNAi
pathway. However, the RNAi pathway includes also other
crucial factors such as the conserved ribonuclease Dicer and
the short noncoding small RNAs (Bartel, 2004; He and Han-
non, 2004; Bagga et al., 2005; Kawamura et al., 2008; Tam et
al., 2008; Watanabe et al., 2008). In agreement with our
findings, Dicer and miRNAs have also been recently found
to be essential for mouse female germ-line meiosis and early
development. It has been shown that depletion of Dicer from
oocytes results in many miRNAs being lost from these cells
(Tang et al., 2007). Moreover, Dicer appears crucial for com-
pletion of meiosis in female germ-line (Murchison et al.,
2007). This suggests that Ago2 might also function during
the process of oocyte maturation, a developmental stage not
examine by experiments reported here. Indeed it could be
postulated that miRNAs may be involved in the turnover of
maternal transcripts essential for successful oocyte matura-
tion.
Our own miRNA screen in conjunction with bioinformat-
ics analysis identified several miRNAs expressed at these
early stages of development as potential candidates to work
with RISC to degrade maternal mRNAs. Of these, several
miRNAs could possibly target and regulate stability of the
Mosg, Gbx2, Fgfr2, and Lepr-2 transcripts. However, it is
also possible that other dsRNAs could be involved such as
the natural siRNAs derived from pseudogenes (Sasidharan
and Gerstein, 2008). Thus, while our study points to an
important role for Ago2 at the earliest stages of mouse
embryogenesis, it remains of considerable future interest to
identify precisely whether and how specific small endoge-
nous dsRNAs might work in conjunction with Ago2 to
regulate mRNA stability at this crucial developmental stage.
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